

The Managing Director
Pakistan Stock Exchange Limited
Stock Exchange Building
Stock Exchange Road
Karachi – 74000

ICI PAKISTAN LTD.

ICI House, 5 West Wharf, Karachi 74000

T +92 21 3231 3717-22 F +92 21 3231 1739 UAN 111 100 200

www.ici.com.pk

April 24, 2019 Ref#ComSec/PSX/13/2019

Dear Sir,

BOARD MEETING RESULTS FOR THE 3RD QUARTER / NINE MONTHS ENDED MARCH 31, 2019

We wish to inform you that the Board of Directors of ICI Pakistan Limited at its meeting held on April 24, 2019, has approved the un-audited accounts of the Company for the 3rd Quarter / Nine months ended March 31, 2019, and are pleased to announce the consolidated and un-consolidated results of the same which are attached as **Annexure 'A' & 'B'**, respectively.

DIVIDEND

NIL

FINANCIAL RESULTS

Attached as Annexure 'A' (consolidated results) and Annexure 'B' (unconsolidated results).

OVERVIEW

On a consolidated basis, including the results of the Company's subsidiaries, ICI Pakistan PowerGen Limited, Cirin Pharmaceuticals (Private) Limited and NutriCo Morinaga (Private) Limited, net turnover for the nine months under review at PKR 43,937 million translates into a 20% increase as compared to the SPLY, with the Polyester, Soda Ash and Chemicals & Agri Sciences Businesses posting topline growth of 31%, 34% and 11%, respectively.

Operating result for the nine months at PKR 3,523 million is 2% lower in comparison to the SPLY, due to lower performance in the Polyester and Life Sciences Businesses by 148% and 74%, respectively. This was, however, partially offset by improved performance in the Soda Ash and Chemicals & Agri Sciences Businesses by 29% and 257%, respectively. Lower operating result in the Polyester Business is attributable to net realisable value adjustments following a decline in prices of polyester staple fibre (PSF) on higher carrying inventory required to cover the shutdown period in the second quarter, which was partially offset by contributions from new export markets in the third quarter. The operating result of Life Sciences Business was lower as sales were adversely affected by the ban on import and marketing of recombinant bovine

ohn





somatotropin (rbST) injections, along with higher costs due to a surge in imported raw material prices and rupee devaluation.

The improved performance achieved by the Soda Ash Business was mainly due to higher sales volumes attributable to the commissioning and commercial operation of the 75,000 tons per annum plant expansion. The Chemicals & Agri Sciences Business showed improved performance on the back of strong operating results delivered by the Agro Chemicals segment, coupled with higher sales of sunflower seeds as a result of the subsidy announced by the government.

Profit after tax (PAT) for the nine-month period under review at PKR 1,773 million is 35% lower than the SPLY. This was due to higher finance costs by PKR 664 million owing to increased interest rates and higher debt due to a shift in the Company's payment policy from Usance LC to Sight LC to minimise foreign exchange losses. Additionally, lower share of profit from associate and a higher effective tax rate due to non-availability of tax credits, which were available during the SPLY on the Light Soda Ash expansion project, negatively impacted the profits.

Earnings per share (EPS) for the nine months period under review, at PKR 19.10, is 35% lower as compared to the SPLY.

On an unconsolidated basis, PAT for the nine months period under review at PKR 1,655 million and EPS at PKR 17.91 are 33% lower than the SPLY.

The Company will send you the required number of printed unaudited Accounts for distribution amongst the members of the Exchange. The full set of Financial Results will shortly be available on our website www.ici.com.pk.

Yours faithfully,

Nausheen Ahmad

Company Secretary

cc: The Commissioner

Company Law Division, Securities & Exchange Commission of Pakistan

NIC Building, Jinnah Avenue, Islamabad.

The Commissioner

Laulieu almad

Securities Market Division, Securities & Exchange Commission of Pakistan

NIC Building, Jinnah Avenue, Islamabad.



ANNEXURE - A

ICI Pakistan Limited Condensed Interim Consolidated Statement of Profit or Loss (Unaudited) For the Nine Months Ended March 31, 2019

Amounts in PKR '000 For the For the For the For the 3 months 9 months 3 months 9 months ended ended ended ended March 31, March 31, March 31, March 31, 2018 2018 2019 2019 36,745,498 13,225,545 Net turnover 15,529,172 43,936,817 (29,806,050)(10,717,354)(12,782,102)(36,848,782)Cost of sales 6,939,448 2,747,070 7,088,035 2,508,191 **Gross profit** (2,206,348)(827,700)(2,477,266)(726,021)Selling and distribution expenses (345,620)(1,087,940)(344,625)(1,151,257)Administration and general expenses 1,437,545 3,581,843 1,573,750 3,522,829 Operating result (181,086)(395, 236)(355,500)(1,059,182)Finance costs (98, 257)(336,459)(18,896)(235,737)Exchange loss (157,087)(121,881)(63,410)Workers' profit participation fund (61,435)(60,889)(24,564)Workers' welfare fund (19,368)(43, 225)(12,049)(35,542)Other charges (2,523)(32,757)(379,366)(985,213)(457,722)(1,492,782)20,028 88,970 36,545 100,109 Other income 458,539 Share of profit from associate 155,586 324,117 179,501 1,274,225 3,155,278 1,291,642 2,443,134 Profit before taxation (410,212)(343,428)(670,016)(158,445)**Taxation** 1,115,780 2,745,066 1,773,118 948,214 Profit after taxation Attributable to: 1,112,218 2,733,743 Owners of the Holding Company 948,306 1,763,753 Non-controlling interests (92)9,365 3,562 11,323 1,115,780 2,745,066 948,214 1,773,118 (PKR) 19.10 12.04 29.60 10.27 Basic and diluted earnings per share

Page 3 of 4







ANNEXURE - B

ICI Pakistan Limited Condensed Interim Unconsolidated Statement of Profit or Loss (Unaudited) For the Nine Months Ended March 31, 2019

Amounts in PKR '000

	For the 3 months ended March 31, 2019	For the 9 months ended March 31, 2019	For the 3 months ended March 31, 2018	For the 9 months ended March 31, 2018
Net turnover	15,188,354	43,102,799	12,955,990	36,133,049
Cost of sales	(12,533,508)	(36,259,458)	(10,582,665)	(29,513,132)
Gross profit	2,654,846	6,843,341	2,373,325	6,619,917
Selling and distribution expenses	(783,211)	(2,340,832)	(682,634)	(2,095,182)
Administration and general expenses	(333,987)	(1,009,646)	(330,361)	(1,106,891)
Operating result	1,537,648	3,492,863	1,360,330	3,417,844
Finance costs	(348,675)	(1,044,494)	(178,002)	(388,546)
Exchange loss	(18,861)	(234,246)	(97,748)	(335,950)
Workers' profit participation fund	(59,681)	(122,378)	(59,954)	(149,138)
Workers' welfare fund	(19,348)	(45,408)	(23,247)	(57,807)
Other charges	(1,843)	(33,974)	(11,677)	(34,656)
	(448,408)	(1,480,500)	(370,628)	(966,097)
Dividend income	-	255,000	125,000	320,000
Other income	16,148	57,599	24,431	60,805
Profit before taxation	1,105,388	2,324,962	1,139,133	2,832,552
Taxation	(351,280)	(670,397)	(137,028)	(367,575)
Profit after taxation	754,108	1,654,565	1,002,105	2,464,977
	(PKR)			
Basic and diluted earnings per share	8.16	17.91	10.85	26.69





